US1011371077 - Common Stock
BOSTON SCIENTIFIC CORP
NYSE:BSX (4/19/2024, 9:07:06 AM)
67.98
+0.56 (+0.83%)
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 45,000 full-time employees. The Company’s segments include MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy and Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal and pulmonary conditions. Its Urology and Neuromodulation business develops and manufactures devices to treat various urological, neurological movement disorders and pelvic conditions. Its Cardiac Rhythm Management develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment include Interventional Cardiology and Peripheral Interventions. Its Interventional Cardiology develops and manufactures technologies for diagnosing and treating coronary artery disease and structural heart conditions. Its product offerings include 360 Clips and RESONATE, among others.
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS 01752
P: 15086834000
CEO: Michael F. Mahoney
Employees: 45000
/PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module* when it is used to visualize...
/PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first...
/CNW/ -- Recently, Scivita Medical Technology Co., Ltd. ("Scivita Medical") and Boston Scientific Corporation (NYSE: BSX), a leading global medical technology...
/PRNewswire/ -- Recently, Scivita Medical Technology Co., Ltd. ("Scivita Medical") and Boston Scientific Corporation (NYSE: BSX), a leading global medical...
Fellow infant formula maker Reckitt Benckiser was ordered to pay $60 million to a mother whose baby died after eating Enfamil.
Here you can normally see the latest stock twits on BSX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: